This article is more than 5 years old. Information may no longer be current.

VIDEO: Luminate study shows equivalence to anti-VEGF with fewer injections

ByPeter K. Kaiser, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BALTIMORE — Luminate (ALG-1001) from Allegro Ophthalmics met both its primary and secondary endpoints in a phase 2 trial for the treatment of diabetic macular edema, Peter K. Kaiser, MD, said at the Association for Research in Vision and Ophthalmology meeting here. The integrin antagonist was injected monthly for 3 months and then patients were off treatment for 2 months, compared with five monthly injections of bevacizumab. The study showed Luminate was non-inferior to the anti-VEGF treatment with fewer injections.